Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Terenig O. Terjanian"'
Autor:
Zakaria Alameddine, Muhammad Rafay Khan Niazi, Anisha Rajavel, Jai Behgal, Praneeth Reddy Keesari, Ghada Araji, Ahmad Mustafa, Chapman Wei, Abdullah Jahangir, Terenig O Terjanian
Publikováno v:
Current Oncology, Vol 30, Iss 10, Pp 9262-9275 (2023)
Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at
Externí odkaz:
https://doaj.org/article/1b8ec0743ab946eaaebd4e4567cad0a6
Autor:
Luis Chu, Paul M. Hyman, Jacob D. Soumerai, Steven P. Treon, Johannes C. Nunnink, Joseph J. Kash, Zachary R. Hunter, Christopher J. Patterson, Nikhil C. Munshi, Ari David Baron, Paul Musto, Terenig O. Terjanian, Leukothea Ioakimidis, David J. Sharon, Andrew R. Branagan, Elena L. Nawfel, Kenneth C. Anderson
Publikováno v:
Clinical Cancer Research. 15:355-360
Purpose: Thalidomide and its more potent immunomodulatory derivative lenalidomide enhance rituximab-mediated antibody-dependent cell-mediated cytotoxicity. We therefore evaluated lenalidomide and rituximab in symptomatic Waldenstrom's macroglobulinem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36c6e43b9baf44ddd2cb2e675eeae4fa
https://doi.org/10.1158/1078-0432.ccr-08-0862
https://doi.org/10.1158/1078-0432.ccr-08-0862